SL
DGX icon

Salomon & Ludwin’s Quest Diagnostics DGX Stock Holding History

Salomon & Ludwin’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$139K Hold
703
– – 0.01% 195
2025
Q4 		$122K Sell
703
-18
-2% -$3.28K 0.01% 210
2025
Q3 		$129K Buy
721
+703
+3,906% +$125K 0.01% 191
2025
Q2 		$3.18K Hold
18
– – ﹤0.01% 610
2025
Q1 		$3.05K Hold
18
– – ﹤0.01% 555
2024
Q4 		$2.71K Hold
18
– – ﹤0.01% 566
2024
Q3 		$2.79K Sell
18
-18
-50% -$2.69K ﹤0.01% 580
2024
Q2 		$4.93K Buy
36
+18
+100% +$2.46K ﹤0.01% 524
2024
Q1 		$2.4K Sell
18
-158
-90% -$20.5K ﹤0.01% 710
2023
Q4 		$21.4K Hold
176
– – ﹤0.01% 411
2023
Q3 		$21.4K Buy
+176
New +$23.4K ﹤0.01% 411

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Salomon & Ludwin's DGX Position: Q1 2026 in Review

Salomon & Ludwin held its Quest Diagnostics (DGX) position steady in Q1 2026 at 703 shares worth $139K. The position accounts for 0.01% of the portfolio, ranked #195.

Salomon & Ludwin first reported a position in DGX in Q3 2023 and has held it in 11 quarters since. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Salomon & Ludwin held 703 shares of Quest Diagnostics worth $139K as of Q1 2026.
  • Salomon & Ludwin left its Quest Diagnostics share count unchanged in Q1 2026.
  • Quest Diagnostics made up 0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #195 holding.
  • Salomon & Ludwin first reported a position in Quest Diagnostics in Q3 2023 and has held it in 11 quarters since.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.